Comparison of antiplatelet treatment in patients with clopidogrel nonresponders with or without carriage of CYP2C19 polymorphism.
Conclusions: Among clopidogrel nonresponders with cardiovascular disease on 75 mg daily clopidogrel, ticagrelor resulted in a comparable degree of platelet inhibition in all nonresponders compared with 150 mg daily clopidogrel or triple therapy with clopidogrel and cilostazol, irrespective of phenotype.
PMID: 29843492 [PubMed - as supplied by publisher]
Source: The Korean Journal of Internal Medicine - Category: Internal Medicine Authors: Ko YM, Kim JK, Kim JH, Park SH, Choi RK Tags: Korean J Intern Med Source Type: research
More News: Cardiology | Cardiovascular | Cilostazol | Clopidogrel | Heart | Internal Medicine | Plavix | Study